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QoL-AGHDA is designed for use in patients with growth
hormone deﬁciency (GHD). It comprises a 25-item ques-
tionnaire that elicits yes/no responses that are used to
compute an aggregate summary index. A high QoL-
AGHDA score denotes poor HrQoL. The survey sample
consisted of 1000 individuals randomly selected from the
UK Population Preference Panel. Individuals were sent a
modiﬁed form of the QoL-AGHDA (including EQ-5D).
The population data were compared with corresponding
data on patients in UK KIMS (Pﬁzer International Meta-
bolic Database). RESULTS: Completed survey forms
were received from 882 individuals (57% female, median
age 55, range 18–90). The mean QoL-AGHDA scores in
the general population was 6.78 (sd = 5.85, n = 868). The
corresponding mean for patients was 14.71 (sd = 5.58, 
n = 841). There was a high degree of correlation with EQ-
5D. Comparison with corresponding data for patients
diagnosed and/or treated for GHD indicate signiﬁcant 
differential patterns of response, with much higher 
QoL-AGHDA scores commensurate with lower levels 
of HrQoL in this group. CONCLUSIONS: This study
reports for the ﬁrst time on the use of QoL-AGHDA in
a UK general population setting. It provides important
evidence on the performance of this condition-speciﬁc
measure as well as calibrating normative reference values.
Additionally it conﬁrmed the discriminant validity of the
measure and demonstrated the health burden of patients
with GHD.
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OBJECTIVES: To analyze how newly HIV+ diagnosed
patients are managed in 3 French HIV Public Hospitals.
METHODS: STAR is an observational study designed to
prospectively collect electronic data on immunological
and virological status, anti-retroviral therapy (ART) and
medical cost of HIV+ patients. Newly diagnosed (de
novo) patients are exhaustively included in the cohort
since February 2002 in order to identify therapeutic
strategies in the setting of clinical practice. RESULTS: At
the end of March 2003, a total of 328 de novo patients
(65% male) were included, of mean age 36.8 ± 10.5 years,
mainly infected through sexual contacts (49% heterosex-
ual and 27% homosexual). At the time of HIV diagno-
sis, mean CD4 counts and viral load were respectively
368 ± 278 /mm3 and 111,947 ± 164,986 copies/ml. Fifty-
ﬁve patients (17%) had already clinical AIDS status 
and the mean time from seropositivity was 248 ± 104
days. In March 03, 59.5% of patients were without ART
(among whom 94.4% were totally ART-naïve), 36%
were treated with a combination of 3 anti-retrovirals and
4% with 4 anti-HIV drugs. The most frequent combina-
tions were 3 NRTIs (38%) and 2 NRTIs + 1 boosted Pro-
tease Inhibitor (29%). The mean time between HIV
diagnosis and initiation of ART was 66 ± 72 days and the
mean duration of follow-up of non-treated patients was
237 ± 107 days. During the observation period, 29.2%
of treated patients had their treatment changed at least
once, mainly because of drug-related intolerance. A total
of 38% remained under the same ARV combination but
changed at least one molecule. CONCLUSION: These
ﬁndings obtained after 14 months showed signiﬁcant
trends in the management of newly HIV+ diagnosed
patients with a large majority of patients without ART, a
high diversity of initial ART regimens and a high fre-
quency of early interruption.
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OBJECTIVES: Assess the association between unsuccess-
ful initial empiric antibiotic therapy and Health care
resource use among patients undergoing surgery for com-
munity-acquired intra-abdominal infections (CIAI) in
Spain. METHODS: Records of patients who underwent
surgery for CIAI from October 1998 to August 2002 in
hospitals in Spain were reviewed. Empiric antibiotic
therapy was classiﬁed as successful if CIAI was resolved
with initial therapy or with decrease from initial therapy;
and as unsuccessful if IAI was resolved with additional
therapy, additional surgery, died in hospital, or re-
hospitalized within 30 days of discharge. Health care
resource use was measured by hospital length of stay in
days (LOS) and days on IV antibiotic therapy and were
compared between patients with successful and unsuc-
cessful therapy using the non-parametric Kruskal-Walis
test. Least square regression analyses with log transfor-
mation of the outcome variables were performed to assess
associations between unsuccessful IEAT and Health care
resource use measures, after adjusting for patients’ demo-
graphic and co-morbid characteristics as well as site/type
of infection. Four hundred twenty-ﬁve patients were
included. RESULTS: Mean (SD) age was 53.2 (20.7);
40.5% female. 315 (74.1%) patients had successful
therapy (resolved with initial or with decrease from initial
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therapy in 66.8% and 7.3% of patients, respectively). 110
(25.9%) patients had unsuccessful therapy (9.4%
required additional antibiotic therapy; 4.0% died in 
hospital; 4.5% got re-hospitalized within 30 days of 
discharge). Mean LOS (SD) was 10.7 (7.2) versus 18.7
(16.2) days (p < 0.01) among patients with successful
versus unsuccessful therapy; mean days on IV antibiotic
(SD) therapy was 7.5 (3.8) versus 13.1 (12.0) days (p <
0.01). CONCLUSION: Multivariate analyses showed
that unsuccessful therapy was associated with a 39% (p
< 0.01) increase in both LOS and days on IV antibiotic
therapy, after adjusting for patients characteristics and
site/type of infection. Among patients undergoing surgery
for CIAI, unsuccessful initial antibiotic therapy increases
length of hospital stay and number of days on IV antibi-
otic therapy.
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OBJECTIVE: To determine whether there is association
between skin tattoos, Hepatits-B and prisons, to investi-
gate risk behaviors for Hepatitis-B and to describe char-
acteristics of person who have tattoos. METHODS: This
retrospective study consisted of a self-administered
survey, and an ELISA blood test for viral hepatitis B. The
study sample consisted of all 1/2000 privates at Adisorn
Fort Hospital Saraburi who had tattoos (n1 = 46) and
simple random sampling of another group of 46 volun-
teer privates who did not have tattoos. RESULTS: All pri-
vates (N = 92) were male, age 22.88b 1.41 years, 67
(72.8%) had graduated from elementary and high school,
29 were positive for Hepatitis-B antibodies (31.5%), 41
(44.6%) had sex with prostitutes, 3 (3.3%) did not 
use condom, 4 (4.3%) shared razors, 1 (1.1%) shared
needles, 25 (27.2%) had been in jail, 87 (94.6%) drank
alcohol, 43 (46.7%) had used amphetamines. Twenty
(28.6%) had tattoos on 2 arms. Ten (14.3%) had tattoos
on their back, 9 (19.6%) obtained their tattoos while in
prison, 15 (32.6%) had a tattoo that was greater than
20% of the body’s surface area. There was an association
between skin tattoos and Hepatitis B (Chi Square, p < .01,
OR: 15.9, 95% CI: 2.1–18.8), There was no association
between having been in jail and Hepatitis-B. Logistic
regression was employed to ﬁnd factors for Hepatitis-B.
The variables that were associated with Hepatitis-B
(<0.05) were entered procedure to identify association
with Hepatitis-B. Hit rate was 87.9, Pseudo R Square
0.464, Skin tattoos, a history of a family member with
Hepatitis-B, and sharing needles increased the chance of
getting Hepatitis-B. CONCLUSIONS: There were associ-
ations between jails and tattoos and viral hepatitis-B.
Hygiene in tattoo’ shops should be controlled by the 
government.
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OBJECTIVES: ESAC (European Surveillance of Antibi-
otic Consumption, granted by DG SANCO of the EC) is
an international network of national surveillance systems,
aiming to collect comparable antibiotic consumption data
in Europe. During the ﬁrst phase, data accessibility and
validity, as well as strengths and weaknesses of national
systems were assessed. METHODS: Quarterly data were
to be collected retrospectively (1997–2001) from ambu-
latory (AC) and hospital care (HC) in 31 countries, using
ATC/DDD classiﬁcation (WHO, version 2001), and
expressing results in DDD/1000 inhabitants per day
(DID). RESULTS: AC use data were provided by 25
countries; 21 were suitable for international comparison.
The remaining 3 were not comprehensive or not in a
format enabling international comparison (TU). Quar-
terly AC data were delivered by 10 countries. HC use data
were provided by 23 countries; 21 were suitable for inter-
national comparison, 14 of them were based on a limited
sample. In 2001, AC use in Europe varied between 10.0
DID (NL) and 32.9 DID (FR). Other high consumers
were (in decreasing order) GR, IT, LU, PL, PT, BE 
and SK, all with a total use exceeding 24 DID. During
the observation period of 5 years, consumption clearly
increased in GR and PL and decreased in BE and ES. High
seasonal ﬂuctuations in AC were observed in BE, GR, 
PL and SI. Large regional differences could be observed
in consumption patterns. Northern European countries
(NO, SE, FI, DK, NL) are low consumers using com-
monly narrow spectrum penicillins while Southern 
European countries are high consumers using broad spec-
trum penicillins and exceptionally high proportions of
cephalosporins, macrolides and quinolones. CONCLU-
SIONS: An intriguingly high variation in antibiotic use in
Europe was observed and needs to be related to social,
cultural and economic determinants of use as well as to
variation in resistance patterns. Especially in AC, coun-
tries seem to cluster in regional consumption patterns.
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OBJECTIVES: To measure the adherence to antibiotic
treatment guidelines distributed to physicians in Wash-
ington State, USA. The Washington Department of
Health, Washington State Medical Association (WSMA)
and Health Plans understand that antibiotic resistance is
